Epidemiological characteristics and early predict model of children Mycoplasma Pneumoniae Pneumonia outbreaks after the COVID-19 in Shandong.

Publication date: Aug 27, 2024

Since October 2023, a significant outbreak of Mycoplasma Pneumoniae Pneumonia (MPP) has been observed in children in northern China. Chinese health authorities have attributed this epidemiological to immune debt resulting from the relaxation of coronavirus disease 2019 (COVID-19) control measures. This study described the epidemiological features of Mycoplasma pneumoniae (MP) prevalence in children and developed a straightforward prediction model to differentiate between MPP and viral pneumonia in children. The infection rate of MP in children notably increased from 8. 12 in 2022 to 14. 94% in 2023, peaking between October and November, especially among school-age children. Logistic regression screening identified four key indicators: Age, D-Dimer levels, erythrocyte sedimentation rate, and gender. The developed nomogram exhibited a receiver operator characteristic curve-area under the curve (ROC-AUC) of 0. 858, with external validation confirming an ROC-AUC of 0. 794. This study examined the epidemiological characteristics of MPP prevalence in children in Shandong Province during and after the COVID-19 pandemic. An early predict model was developed and validated to differentiate between Mycoplasma Pneumoniae and viral infections.

Open Access PDF

Concepts Keywords
China Adolescent
Pneumoniae Child
School Child, Preschool
Viral China
COVID-19
COVID-19
Disease Outbreaks
Epidemiology
Female
Humans
Infant
Male
Mycoplasma pneumoniae
Mycoplasma Pneumoniae Pneumonia
Nomogram
Outbreak
Pneumonia, Mycoplasma
Prevalence
ROC Curve
SARS-CoV-2

Semantics

Type Source Name
disease MESH Pneumonia
disease MESH COVID-19
disease MESH viral pneumonia
disease MESH infection
disease VO age
disease VO erythrocyte
drug DRUGBANK Saquinavir
disease MESH viral infections
drug DRUGBANK Coenzyme M
disease MESH emergency
disease VO Optaflu
disease MESH respiratory infections
disease VO Respiratory syncytial virus
disease MESH influenza
disease MESH interstitial lung disease
disease MESH asthma
pathway KEGG Asthma
drug DRUGBANK (S)-Des-Me-Ampa
disease VO population
disease VO Viruses
disease MESH co infection
disease IDO history
disease MESH chronic diseases
disease MESH autoimmune disease
disease MESH malignancy
drug DRUGBANK Gold
disease IDO assay
disease IDO blood
disease VO manufacturer
drug DRUGBANK Fibrinogen Human
disease MESH clinical importance
drug DRUGBANK Dichloroacetic Acid
drug DRUGBANK Oxygen
disease MESH respiratory diseases
disease MESH complications
disease MESH inflammation
disease IDO intervention
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Sulpiride
disease MESH Mycoplasma pneumoniae infections
disease MESH hypokalemia
drug DRUGBANK Isosorbide Mononitrate
disease IDO cell
disease MESH respiratory syncytial virus infection
disease MESH syndrome
disease MESH Chlamydia Pneumoniae infection
disease MESH bronchitis
drug DRUGBANK Guanosine
disease IDO host
disease MESH thrombosis

Original Article

(Visited 2 times, 1 visits today)